Enanta Pharmaceuticals (ENTA) Scheduled to Post Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) is scheduled to release its earnings data after the market closes on Monday, May 6th. Analysts expect Enanta Pharmaceuticals to post earnings of ($1.26) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The company had revenue of $18.00 million during the quarter, compared to analysts’ expectations of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Stock Up 4.8 %

ENTA stock traded up $0.63 during mid-day trading on Tuesday, hitting $13.88. The company had a trading volume of 42,809 shares, compared to its average volume of 249,247. The company has a market capitalization of $293.70 million, a price-to-earnings ratio of -2.02 and a beta of 0.47. Enanta Pharmaceuticals has a 12-month low of $8.08 and a 12-month high of $37.75. The company has a 50-day moving average price of $14.83 and a 200 day moving average price of $11.89.

Analysts Set New Price Targets

ENTA has been the topic of several recent research reports. StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, April 6th. JPMorgan Chase & Co. reduced their price objective on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Thursday, February 8th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $19.33.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.